Index

Note: questionnaire references at the end of the book are in italics.

ABC study, 208, 210–211
abciximab, 133
ABO blood group system, 37
discovery, 8, 28
incompatibility, 44
platelets and, 37
N-acetylhistidine in hepatic
ischemia–reperfusion injury
prevention, 294
acetylsalicylic acid, 132
acid-base disturbances with
excessively citrated salvaged
blood, 181
acidosis, 76–7
metabolic, 116, 181
ACT (Anemia of Cancer Therapy)
study, 248–9
activated clotting time, 120
activated factor VII see factor VII
activated partial thromboplastin time
(aPTT), 114, 119, 121
activated protein C, 113, 134
active topical hemostatic
agents, 148–9, 149–52
acute lung injury (TRALI), 42, 47–9,
73, 159
acute normovolemic hemodilution
see hemodilution
adenosine modulators acids in hepatic
ischemia–reperfusion injury
prevention, 299
adhesives/glues, tissue, 149–52
history, 144
surgical settings, 151–2
advanced directive, 20
age and autologous blood
collection, 176
AIDS (and HIV infection), 10–11, 72–3
allergic reactions, 41
allogeneic transfusion see transfusion,
allogeneic
altruism, 3, 9
e-aminocaproic acid (EACA), 93–4,
130, 184–6, 227
AMP, cyclic, 107
Ances, Dr and Mrs. Hughes
(a Jehovah’s Witness), 323–4
anemia, 61–82, 342
etiologies, 62–5
oncologic disease see cancer
in ICU, 65, 208–9
pathophysiology, 341–2
pediatric, 234–6
limitations in treatment of, 223
physiologic response, 66–70
pre-operative, 86, 161–2

© 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.
anemia (continued)
transfusion trigger/threshold
defined by risk of transfusion
vs risk of, 32–3, 62, 70–72, 78,
207, 210, 345
anesthesia, 93, 162, 341
controlled hypotensive
see hypotensive anesthesia
anesthetic agents and normovolemic
hemodilution, 169–70
angiotensin receptor antagonists in
hepatic ischemia–reperfusion
injury prevention, 294–5
animal blood transfusion, 5–7
antibodies (immunoglobulins)
to erythropoietin, 258
to red cells, 45, 46, 47
see also autoantibodies
anticoagulants
circulating (endogenous), 118
use, 132–4
autologous blood, 177, 178
donated (allogeneic) blood, 8
antidiuretic hormone analog
see desmopressin
anti-factor Xa activity assay, 121
antifibrinolytics, 130–131, 184–6
in blood conservation, 184–6
children, 227
in topical products, 150
antiplatelet agents, 132–3, 344
antithrombin, 113–14
antithrombotic drugs, 133–4
apheresis (pheresis), 29
platelet, 38
apixaban, 134
aprotinin, 94, 130–131, 150
in blood conservation, 94, 184
children, 227
argatroban, 134
arterial thromboembolism risk with
peripheral red blood cell
transfusion, 260–261
artificial blood (carriers of
oxygen), 271–88, 342–3
defining the need for, 274–6
hemoglobin-based, 24–5, 97,
216–17, 274–83
aspirin, 132
assent (child), 21
autoantibodies
(autoimmunoglobulins),
anticoagulant, 118
to factor VIII, 187
autologous blood collection/
donation, 164–82
DHS pamphlet and consent
issues, 335
pre-operative, 92–3, 174–7, 339
collection technique, 175
contraindications, 175–6
cord blood, 226, 229–30
criterion for, 175
Jehovah’s Witnesses, 317
normovolemic hemodilution as
alternative to, 174
autologous blood transfusion
(autotransfusion), 89, 90, 159, 196
children, 225–7, 231
Jehovah’s Witnesses and, 317
autologous intraoperative cell salvage
see cell salvage
Avitene, 179
bacterial contamination, 49–50
Bioglue®, 144
bivalirudin, 134
bleeding see blood loss
bleeding disorders see coagulation
bleeding time, 119–20, 121
blood
artificial see artificial blood
autologous see autologous blood
collection; autologous blood
transfusion
conservation, intra-operative,
88–95, 164–91
children, 227–8
pharmacological agents for,
182–91
see also specific methods
donation see donation
early beliefs and practices, 2–4
loss see bleeding
microparticles, 111–12
oxygen transportation, 272–4
Index 349

blood groups
  ABO see ABO blood group system
  antibodies (red cell), 45, 46, 47
blood indices in anemia of
cancer, 252–3
blood loss (bleeding; hemorrhage), 63
  assessing risk of, 118
  children, 227
  burn surgery, 233
  cardiac surgery, 230, 231
  craniosynostosis surgery, 232
  hepatic surgery, 232–3
  orthopedic surgery, 231
  trauma surgery, 233–4
blood products/components, 12, 35–40, 344
bovine thrombin spray in
  intraoperative blood salvage, 179
Brown, Mrs. (Jehovah’s Witness) and
  the law, 321–2
burn surgery, 233
C1 inhibitor, 113
  in hepatic ischemia–reperfusion
  injury prevention, 300–301
calcium, homeostatic disturbances, 76
  with excessively citrated salvaged
  blood, 181
calcium channel antagonists for
  controlled hypotension, 195–6
cancer (malignancy; oncologic
disease)
  anemia of, 247–70
  children, 236
  current treatment
    recommendations, 263–4
  diagnostic evaluation and risk
  assessment, 252–4
  epidemiology and pattern of
  treatment, 248–9
  options for treatment, 254–63
  pathophysiology, 250–251
  prognostic significance and
  rationale for correction, 249–50
bleeding dyscrasias, 118
intra-operative cell salvage in
  patients with, 91, 178–80
  transfusion-associated recurrence, 85
canister collection technique (blood
  salvage), 177
capacity and its lack see competence;
  incompetence
  cardiac death, donation (of liver) after
  (DCD), 292–3, 293–4, 296, 299,
  303, 304
cardiac index, 213
  cardiac output (CO)
    assessment, 212
    increasing, 216–17
  cardiac surgery, 230–231
    children, 230–231
  factor VII (recombinant) use, 187–8

pressure see hypertension;
  hypotensive anesthesia;
  hypotensive transfusion
  reactions
refusal see refusal
salvage see cell salvage
substitutes, 24–6, 96–7
transfusion see transfusion
viscosity see viscosity
blood groups
  ABO see ABO blood group system
  antibodies (red cell), 45, 46, 47
Index

cardiac surgery (continued)
fibrinogen use, 189
Jehovah’s Witnesses and, 14, 173, 230, 231
open, 230, 331–2
cardiopulmonary bypass (CPB), 117–18, 189
Jehovah’s Witness and, 173, 231
steroids with, 295
cell (blood) salvage (and cell-saver), intra-operative, 23, 89–92, 177–82, 228, 339
children, 228, 230, 231, 233
contraindication, 91, 178–80, 345–6
Jehovah’s Witnesses and, 317
cellulose-based hemostatic agents, 153
central lines in children, 228
cerebral vasculature and blood flow nitroprusside effects, 193–4
in normovolemic hemodilution, 171–2
cerulin fatty acids in hepatic ischemia–reperfusion injury prevention, 299
chemotherapeutic drugs, 35, 248, 249, 249–50, 251, 254, 255, 256, 263, 264
children (pediatric population incl. neonates and infants), 222–46
antifibrinolytics, 185–6
consent issues, 21–2
normovolemic hemodilution, 169
specific consideration of transfusion in, 222–3
transfusion-free surgery and limited transfusion need, 343
applications in specific surgical situations, 229–36
methods of, 223–9
see also minors
cilostazol, 133
circulatory overload, transfusion-associated (TACO), 43, 74
citrate blood, 8
autologous, 177, 178
excess citrate causing calcium, 181
clamping and hepatic ischemia–reperfusion injury prevention
continuous, 297, 298
intermittent, 297, 298
clopidogrel, 132–3
clotting see coagulation; coagulation factors
coaulation (clotting), 102–43, 145
disorders (incl. bleeding disorders), 113–18, 340–341
with intraoperatively salvaged blood, 180
medical conditions causing, perioperative considerations, 160
postoperative, 345
intraoperative management, 125–30, 145–7
pharmacological manipulation see drugs
as phase in hemostasis, 107–10
phases (five), 102–12, 125
preoperative management, 93–4
tests, 118–21
coagulation (clotting) factors, 107–8, 145
in intraoperatively salvaged blood, dilution, 180
synthetic, 97
see also specific factors
Cobbs v. Grant, 319–20
Code of Ethics, 21, 22
cold preservation/storage (cryopreservation) of liver, 291–2
static (SCS), 293, 302, 303, 304
collagen-based hemostatic agents, 153
in intraoperative blood salvage, 179
colloids
intraoperative, 163–4
in normovolemic hemodilution, 92, 163, 166, 167
Collostat, 179
competence (and capacity), 20–21
adults, 320–321
Jehovah’s Witnesses, 320–321
Index 351

children, 21
lack see incompetence
complement system and hepatic ischemia–reperfusion injury prevention, 299–301
complete blood count (CBC) in anemia of cancer, 252
connecting segment-1 peptide in hepatic ischemia–reperfusion injury prevention, 296–7
consent, 20–22, 319–20
informed, 20–21, 319–21
physician verification, 334
physician and hospital liability, 333
refusing to see refusal
continuous clamping (CP) and hepatic ischemia–reperfusion injury prevention, 297, 298
controlled hypotension, 192–6
Cooley, Dr Denton, 14, 331–2
cord blood for perioperative autologous transfusion, 226, 229–30
coronary blood flow in normovolemic hemodilution, 170–171
sodium nitroprusside affecting, 193
corticosteroids in liver surgery or transplantation, 131, 295–6
cost-effectiveness (in surgery) blood products, 83–4
blood salvage, 178
see also economic cost
craniosynostosis surgery, 232
Cruzan v. Missouri Dep’t of Health, 320
cryoprecipitate, 40
intraoperative, 189
cryopreservation (cold preservation) of liver, 291–2
crystalloids intraoperative, 163
in normovolemic hemodilution, 92, 164, 166, 167
cyanide toxicity with sodium nitroprusside, 194–5
cyanoacrylate, 144
cyclo AMP, 107
cytokines, inflammatory
in cancer patients, 257, 259
suppressing erythropoiesis, 250–251, 255
in liver surgery/transplantation in ischemia–reperfusion injury, 290
modulation of, 295–6
Dark Ages, 3
DDAVP see desmopressin
delayed hemolytic transfusion reactions, 43, 44, 46–7
Denis, Jean Baptiste, 5–7
Department of Health Services (State) pamphlet and consent, 333
desmopressin (DDAVP; vasopressin/ADH analog), 114, 131
in blood conservation, 182–3
children, 227
diaspirin (HemAssist), 277, 277–8
dilutional coagulopathy, 116
dipyridamole, 133
disseminated intravascular coagulation, 117
doctor see physician donation, 29
altruism, 3, 9
blood, 338
autologous see autologous blood collection
DHS pamphlet and consent issues, 335
donor recruitment programs, 29
historical perspectives, 3, 8
liver, 292
increasing donor pool, 290, 299
organ (in general) Jehovah’s Witnesses and, 24
living see living-donors
plasma products, safety considerations, 147
testing of donors, 344
Dorone, Mr. (Jehovah’s Witness) and the law, 322
Index

drug(s)
  in controlled hypotension, 192
  in hepatic ischemia–reperfusion injury prevention, 293–301
  manipulating coagulation cascade
  anticoagulant see anticoagulants
  hemostatic see hemostatic drugs
  procoagulant, 131–2
  see also specific drugs

drug-induced disorders
  anemia with chemotherapeutic drugs, 35, 248, 249, 249–50, 251, 254, 255, 256, 263, 264
  of hemostasis, 117
  Dura, Mrs. (Jehovah’s Witness) and the law, 324–6

ecarin clotting time, 120–121

economic cost
  allogeneic transfusion, 84
  autologous blood collection and transfusion, 90, 176–7
  blood products, 338
  intraoperative blood salvage, 178
  see also cost-effectiveness
  EGF in hepatic ischemia–reperfusion injury prevention, 294
  electrolyte disturbances with excessively citrated salvaged blood, 181
  eltrombopag, 131
  emergency surgery in adults
    Jehovah’s Witnesses, 322–6
    with no information available, 326
  endothelium (and endothelial cells) in hemostasis, 103–4, 112–13
  Enlightenment, 3
  enterocolitis, necrotizing, 229
  epidermal growth factor in hepatic ischemia–reperfusion injury prevention, 294
  epsilon amino caproic acid (EACA), 93–4, 130, 184–6, 227
  eptifibatide, 133
  erythrocytes see red blood cells
  erythropoiesis (red blood cell formation/production), 61–2
  agents increasing see erythropoietin
  decreased/suppressed, 64
  in cancer, 250–251
  preoperative stimulation, 86–7
  erythropoietin (erythropoiesis-stimulating agents/ESAs), 61–2, 217, 223–5, 339–40
  recombinant human (rHuEPO), 189–91, 217
    contraindications, 346
    iron use with, 87, 190, 258–9, 344
    post-operative, 96
    pre-operative, 86–7, 176
    refractoriness to, 343
  recombinant human (rHuEPO) in cancer patients, 254–9, 263–4
  current recommendations, 263–4
  decreased use leading to increased transfusion, 263
  recombinant human (rHuEPO) in children, 223–5
    burn surgery, 233
    craniosynostosis surgery, 232
    hematopoietic malignancy, 236
    ICU patients with anemia, 236
    liver surgery, 233
    orthopedic surgery, 231–2
    premature neonates, 234, 236
  ethical issues, 19–27
  expanded criteria donors (ECD) of liver, 290, 291, 292, 306

  factor II (prothrombin), 107, 108, 109, 115, 187
  factor V, 109–10
    deficiency, 115
  factor VII, 107, 108
    deficiency, 115, 132, 227
    recombinant activated factor VIIa, 94–5, 132, 186–8, 340
    adverse effects, 188
    children, 227
  factor VIII, 40, 108
    concentrates (incl. cryoprecipitates), 40, 114
    recombinant, 189
    DDAVP effects, 114, 182, 183
    deficiency, 104–5, 108, 114–15
    inhibitors/autoantibodies, 187
factor IX, 107, 108  
deficiency, 108, 115  

factor X/Xa, 107, 108, 109, 186–7  
anti-Xa activity assay, 121  

factor XI, 108  
deficiency, 115  

factor XIII, 110, 145, 186, 189  
deficiency, 40  

family members disagreeing with Jehovah’s Witness refusal of blood, 328–9  

fatty (steatotic) liver, ischemia–reperfusion injury and its prevention, 292, 294–5, 295–6, 296–7, 297–8, 299, 303  

febrile reactions (fever), 41, 49, 75  
ferrous sulfate, 217  

fibrin, 145  
degradation see fibrinolysis  
formation, 103, 110, 145  
as glue/adhesive/sealant, 149–52  
surgical settings, 151–2  

fibrinogen, 108, 110, 145  
deficiency, 40, 115  
use, 189  
topical, 148, 149–50  

fibrinolysis, 103, 110–112  
balance between clot formation and, 103  
drugs inducing see thrombolytic drugs  
inhibitors see antifibrinolytics  
preoperative management, 93  
thromboelastography in, 123  
fluid administration (for volume replacement)  
acute normovolemic hemodilution, 167–8  
intraoperative, 163–4  
fluorocrit, 284  
Fluosol-DA, 283  
folate deficiency, 65, 161–2  
fondaparinux, 134  
fresh frozen plasma (FFP), 38  
uses, 115, 117, 124  
intraoperative, 128  

frozen plasma (FP)  
within 8 hours see fresh frozen plasma  
within 24 hours (FP24), 38  

full (complete) blood count in anemia of cancer, 252  

gelatin-based hemostatic agents, 153–4  
in intraoperative blood salvage, 179  
Gelfoam, 179  
glues see adhesives  
glycoprotein IIb/IIIa receptors, 106, 107  
antagonists/inhibitors, 107, 132, 133  
graft-vs-host disease, 42  

Greeks, ancient, 2  

haptoglobin, 64  
HBOC-201 (Hemopure), 24–5, 277, 278–9  

heart surgery see cardiac surgery  
Helistat, 179  
HemAssist, 277, 277–8  
hematocrit  
anemia of cancer, 252  
in normovolemic hemodilution, 164–74  

hematological diseases, 65  
malignant, in children, anemia, 236  
hematological indices in anemia of cancer, 252–3  
hematological status, pre-operative, 86  
hemodilution, acute normovolemic/isovolemic (ANH), 69–70, 92–3, 164–74, 339  
children, 225–6  
contraindications, 165, 340  
hemoglobin (Hb)  
critical, 66, 67, 70  
hemoglobin-driven blood transfusions, concepts forming basis for use, 31–2  
in intraoperative cell salvage, 180  
low concentrations, 62  
oxygen and see oxygen
index

hemoglobin (continued)
synthetic Hb-based oxygen carriers, 24–5, 97, 216–17, 274–83
hemoglobin raffimer (Hemolink), 277, 280
Hemolink, 277, 280
hypothermic machine perfusion of liver (before transplantation), 304
Hystoacryl®, 144

IGF-1 in hepatic ischemia–reperfusion injury prevention, 294
immune hemolytic reactions, 74, 75
immune idiopathic thrombocytopenic purpura, 104, 131
immunological effects of transfusion (incl. immunomodulation), 43, 77, 84–5
peripheral red blood cell transfusion, 260
incompetence (and incapacity) in adults
in Jehovah’s Witnesses, 322–6, 327–8
with no information available, 326
infants see children
infections, transfusion-transmitted, 9–11, 41–2, 72–3, 84, 159, 343–4
peripheral red blood cell, 260
plasma products, 147–8
see also sepsis
inflammatory cytokines see cytokines
inflammatory response, systemic, 125
informed consent or refusal see consent; refusal
injuries, surgery for, 233–4
INR see International Normalized Ratio
Instat, 179
insulin growth factor-1 in hepatic ischemia–reperfusion injury prevention, 294
intensive/critical care unit (ICU), 207–21, 341
anemia, 65, 208–9
pediatric, 236
intermittent clamping (IC) in hepatic ischemia–reperfusion injury prevention, 297–8, 305
International Normalized Ratio (INR), 119
normalization, 39–40
iron administrations/supplementation, 217
in cancer patients, 258–9, 262
with erythropoiesis-stimulating agents, 87, 190, 258–9, 344
overload, in peripheral red blood cell transfusion, 261
irradiation blood products, 77
salvaged blood, 91
see also radiotherapy
ischemia, coronary, with sodium nitroprusside, 193
ischemia–reperfusion injury in liver surgery and transplantation, 289–314
ischemic preconditioning (IP) of liver, 297–8, 305
isovolemic hemodilution see hemodilution
Jehovah’s Witnesses, 14, 15, 19, 22–3, 315–32, 336, 340, 343
acceptable products/treatments/procedures, 316–17
cardiac surgery, 14, 173, 230, 231
cardiopulmonary bypass, 173, 231
historical perspectives, 315–16
normovolemic hemodilution, 173
specific issues related to refusal, 320–331
kallikrein, 113
kidney see renal toxicity
kininogen, high-molecular-weight (HMWK), 108, 109, 113
Kupffer cell modulation in hepatic ischemia–reperfusion injury prevention, 296
lactate (blood), 213
Landsteiner, Karl, 8, 28
legal and administrative issues, 315–37, 340
lepirudin, 134
leukocytes (white blood cells)
- depletion filters in cell salvage, 91
- modulation in hepatic ischemia–reperfusion injury prevention, 296
- life-sustaining treatment, refusal of blood as, 319–20
- lipid metabolism, manipulation in hepatic ischemia–reperfusion injury prevention, 299

liver
- coagulopathy in chronic disease, 116
- surgery, 289–314
  - children, 232–3
  - fibrin glues, 151
  - ischemia–reperfusion injury, 289–314
- transplantation, 124, 128, 289–314
  - children, 232, 233
  - Jehovah's Witness, 324–5

see also hepatitis B and C

living-donors
- Jehovah’s witnesses and, 24

liver transplantation (LDLT), 290, 299, 301
  - bloodless, children, 233

living will, 20

low-molecular weight heparin (LMWH), 134

lung injury, acute (TRALI), 42, 47–9, 73, 159

lupus anticoagulant, 118

lysin analogs, 130
  - in blood conservation, 184–6

machine perfusion liver (before transplantation), 302–4

malignancy see cancer

massive transfusion, 116–17

mean corpuscular volume in anemia of cancer, 252, 253

mechanical methods of hemostasis, 145–6

mechanical problems with cell-saver devices, 181

Medieval times (Dark Ages), 3

mesenchymal stem cell therapy in hepatic ischemia–reperfusion injury prevention, 301–2

metabolic acidosis, 116, 181

metabolic complications, 76–7

metalloproteinases and hepatic ischemia–reperfusion injury prevention, 296

methylprednisolone in hepatic ischemia–reperfusion injury prevention, 295–6

microparticles in blood, 111–12

Middle (Dark) Ages, 3

minerals, preoperative requirements, 86–7

minors (children under 18 in USA) and refusal of blood/blood products, 21, 329–31

mature and emancipated minors, 21, 331–2

Modernism, 3

MP4 (MP4OX; Hemospan), 277, 280–281

muscle relaxants (neuromuscular blocking agents) and normovolemic hemodilution, 169–70

myocardium
- ischemia (coronary ischemia) with sodium nitroprusside, 193
- oxygen consumption, and normovolemic hemodilution, 170

NANEX™, 25

near-infrared spectroscopy (NIRS), regional tissue oxygenation, 211, 215

necrotizing enterocolitis, 229

neonates see children

nephrotoxicity see renal toxicity

neuromuscular blocking agents and normovolemic hemodilution, 169–70

newborns see children

nicardipine for controlled hypotension, 195–6

nitroprusside (sodium), 192–4
Index 357

non-immune hemolytic reactions, 74–5
non-steroidal anti-inflammatory agents (NSAIDs), perioperative considerations, 160–161
normothermic machine perfusion in hepatic ischemia–reperfusion injury prevention, 303
normovolemic hemodilution see hemodilution
nutritional status, pre-operative, 85, 161–2
omega-3 fatty acids in hepatic ischemia–reperfusion injury prevention, 299
oncologic disease see cancer
oncotic pressure, colloid, 167
open-heart surgery, 230, 331–2
organ transplantation see donation; transplantation
orthogonal polarization spectral (OPS)/sidestream dark field (SDF), 211, 215
orthopedic surgery, 228, 231–2
oxidative stress inhibition in hepatic ischemia–reperfusion injury prevention, 294, 295–6
oxidized cellulose/regenerated cellulose, 153
oxygen, 61
artificial/synthetic carriers see artificial blood
consumption, 342
minimization to reduce transfusion requirements, 216
myocardial, and normovolemic hemodilution, 170
delivery (and tissue oxygenation), 66, 209–10, 342
compensatory mechanisms maintaining, 68–70, 96, 165, 168–71
inadequate, 31
increasing, 216–17, 346
monitoring adequacy, 211–15
myocardial cardiopulmonary bypass maintaining, 173
in normovolemic hemodilution, 169–70
regional markers, 211, 214–15
transfusion and, 209–10, 216–17
extraction (and extraction ratio; \(O_2\)ER), 69, 212–13
normovolemic hemodilution and, 169, 170
Hb and, 272–4
dissociation curve, 66–7, 272, 273
mixed venous oxygen saturation of Hb (SvO\(_2\)), measurement, 212
synthetic hemoglobin-based carriers of, 24–5, 97, 216–17, 274–83
hyperbaric, 216
transportation in blood, 272–4
Oxygen, 283
parasitic infection, transfusion-transmitted, 42
passive topical hemostatic agents, 148, 149, 152–4
patient blood management, 3, 13–14, 16
Paul Gann Blood Safety Act, 333, 334, 335
pediatrics see children; minors
pentastarch, 167–8, 280
perfluorocarbons, 283–4
peripheral red blood cell transfusion, 259–63
pharmacological agents see drugs
pharmed blood, 25
pheresis see apheresis
phlebotomy, blood loss from, 95, 208
children/neonates, 223
reducing, 215–16
phosphodiesterase inhibitors, 133
physician (doctor)
awareness with critically-ill children, 228–9
consent issues in bloodless program, 333, 334
plasma
product/component therapy, 12, 38–40
safety, 147–8
Index

plasma (continued)
  proteins, platelet receptors for, 107
  proteolytic inhibitors, 113
  volume, and red cell mass, 68
plasminogen activator(s), 111
  uses, 130
plasminogen activator inhibitor type 1 (PAI-1), 111
platelets, 104–7
  activation, 106, 107
  adhesion, 105–6
  aggregation, 105, 106, 107
  measurement (aggregometry), 120
  sodium nitroprusside effects, 194
  bacterial contamination, 49–50
  counts
    intraoperative, 130
    measurement, 119–20, 121
  fibrin and, 110
  function
    nitroprusside effects, 194
    tests, 120
  in hemostasis, 102, 104–7
  inhibitors, 132–3, 344
  transfusions, 35–8
  see also thrombocytopenia
Polyheme, 25, 277, 279–80
Post-modernism, 3
post-operative care, 95–6, 164, 207–21
  bleeding disorders, 345
potassium, elevated (hyperkalemia), 76, 76–7
pregnancy, autologous blood collection, 176
prematurity, anemia of, 234–6
pre-operative autologous donation
  see autologous blood collection
pre-operative period, 160–162
  bleeding risk assessment, 121
  patient optimization, 85–8
procoagulants, 131–2
  microparticles as, 111–12
professionalism, 22
prolysins, 130
Promacta (eltrombopag), 131
prostatectomy, retropubic, recombinant factor VII in, 187
protein(s), plasma, platelet receptors for, 107
  protein C, activated, 113, 134
  protein S, 113
  proteolytic inhibitors, plasma, 113
  prothrombin (factor II), 107, 108, 109, 115, 187
  prothrombin time (PT), 118–19, 121
  pure red cell aplasia, 258
purpura
  immune idiopathic thrombocytopenic, 104, 131
  post-transfusion, 42
quality of life in anemia of cancer, 249
  erythropoiesis-stimulating agents and, 256
radiation see irradiation; radiotherapy
radiotherapy (radiation therapy), 248, 249, 254, 256, 262
  see also irradiation
red blood cell(s) (erythrocytes/RBCs)
  antibodies, 45, 46, 47
  aplasia, pure, 258
  bacterial contamination, 49–50
  blood groups see blood groups
  in cell salvage, as only cell salvaged, 90–91
  destruction/lysis, increased/accelerated, 63, 64, 65, 74–5
  in cancer, 250
formation/production
  see erythropoiesis
  loss, increased, 62, 64
mass
  in anemia of cancer, 252
  etiology of decreases in, 62–3
  measurement, 62
  plasma volume and, 68
  stored packed, Hb-based oxygen carriers compared with, 277
red blood cell transfusion, 30–34
  optimal threshold, 345
  pediatric
    neonatal guidelines, 235
    premature neonates, 234–5
    rhEPO decreasing rates of, 224
peripheral, 259–63

see also hemolytic reactions

Re-enlightenment, 3

refusal of blood/blood products

children/minors, 21

informed, 20, 21, 22

Jehovah’s Witnesses see Jehovah’s Witnesses

legal principles, 319–31

renal toxicity

aprotinin, 184

Hb-based oxygen carriers, 276

renin–angiotensin system modulators in hepatic ischemia–reperfusion injury prevention, 294–5

reptilase time, 119

resuscitation, transfusion role in, 209–11

reticulocyte count/index, anemia of cancer, 252, 253

retropubic prostatectomy, recombinant factor VII in, 187

rivaroxaban, 134

rotational thromboelastometry, 125

seizure risk erythropoiesis-stimulating agents, 258

tranexamic acid, 186

self-determination (bodily), right to, 319, 321

semicontinuous flow devices for intraoperative blood salvage, 177, 178

sepsis, post-transfusion, 42, 49–50

serine protease inhibitors and liver transplantation, 293–4

sodium nitroprusside, 192, 192–4

split liver transplantation, 290, 301

static cold storage (SCS) of liver, 293, 302, 303, 304

steatotic liver, ischemia–reperfusion injury and its prevention, 292, 294–5, 295–6, 296–7, 297–8, 299, 303

stem cell therapy in hepatic ischemia–reperfusion injury prevention, 301–2

steroids in liver surgery or transplantation, 131, 295–6

streptokinase, 130

in hepatic ischemia–reperfusion injury prevention, 293–301

stroke volume, increased, 68, 69, 70, 165, 168, 173

surgery, 14, 83–101, 158–206

blood conservation during see blood

cost-effectiveness of blood products, 83–4

ethical issues, 19–27

hemostasis in, 125–30, 145–7

liver see liver

pediatric, 222–46

post-operative care, 95–6, 164, 207–21

pre-operative period see pre-operative period

transfusion-free/bloodless, 158–206

general considerations, 160–164

historical foundation, 14, 331–2

legal and administrative issues, 315–37, 340

trends and evolution, 96–7, 331

Surgicel, 179

synthetic products coagulation factors, 97

oxygen carriers see artificial blood

systemic inflammatory response, 125

Taylor, Dr, and Mrs. Werth (a Jehovah’s Witness), 322–3

temperature (body), intraoperative, 162–3

see also hypothermia; hypothermic machine perfusion

thiocyanate production from sodium nitroprusside, 195

thrombin, 109, 110, 113, 132, 150

direct inhibitors, 120, 134

use, 148, 149, 150

in intraoperative blood salvage, 179

thrombin time, 119

thrombocytopenia

heparin-induced, 117

thromboelastography in, 123
Index

thrombocytopenic purpura, immune idiopathic, 104, 131
thromboelastography (TEG)/thromboelastometry, 120−121, 121−4
intraoperative, 129
rotational, 125
thromboembolic risks/complications
with antifibrinolytics, 186
with erythropoiesis-stimulating agents, 257–8
with factor VIIa (recombinant), 188
with peripheral red blood cell transfusion, 260–261
Thrombogen, 179
thrombolytic (fibrinolytic) drugs, 130
hepatic ischemia−reperfusion injury prevention, 293−4
thrombomodulin, 103–4, 113
soluble, 134
thromboplastin, 108−9
activated partial thromboplastin time (aPTT), 114, 119, 121
in prothrombin time, 118−19
thrombosis
drugs-associated
see thromboembolic risks endothelial cells and, 104
Thrombostat, 179
ticlopidine, 132−3
tirofiban, 133
tissue adhesives see adhesives
tissue plasminogen activator (tPA), 111
clinical use, 130
topical (local) hemostasis, 143, 148−54, 346
history, 144
tranexamic acid (TXA), 94, 130, 150, 227
in blood conservation, 94, 184−6
children, 227
transfusion, allogeneic (and in general)
clinical utility, 30−40
economic cost, 84
emerging issues, 9−14
Hb-based oxygen carriers and, differences/comparisons, 282
history, 1−18, 28−9
massive, 116−17
neonatal, guidelines, 235
paradigm shift, 14−16
pediatric see children reducing/limiting requirements, 216
children see children
in liver surgery and transplantation, 289−314
options and techniques, 159, 196, 216
in resuscitation, role, 209−11
risks/hazards/adverse reactions, 9−13, 41−50, 72−7, 84−5, 96, 159, 339, 345
balancing benefits and, 28−60
infection see infection surgery and see surgery triggers/thresholds, 32−3, 62, 70−72, 78, 207, 210, 345
transplantation (organ), 23−4
donation see donation
Jehovah’s Witnesses, 317−19
liver see liver trauma surgery, 233−4
umbilical cord blood for perioperative autologous transfusion, 226, 229−30
unconscious Jehovah’s Witness, 322, 323, 325, 327−8
urokinase (uPA), 111
clinical use, 130
vascular phase of hemostasis, 102, 103−4
vasoconstriction in hemostasis, 103
vasodilators, controlled hypotension with, 192−6
vasopressin analog see desmopressin
vein-to-vein transfer, 8, 9
venous arterial management protection plus (VAMP Plus), 95
venous oxygen saturation, mixed (SvO₂), measurement, 212
venous thromboembolism risk with peripheral red blood cell transfusion, 260−261
viral infections, transfusion-transmitted, 9–11, 41, 72–3
plasma products, 147–8
viscosity, blood, 68–9
normovolemic hemodilution
and, 168
vitamin B₁₂ deficiency, 65, 161–2
vitamin K deficiency, 86, 115, 116, 119
volume replacement see fluid administration
von Willebrand disease (vWD), 40, 114, 128, 131
von Willebrand factor (vWF), 35, 40, 104, 107, 114
DDAVP effects, 114, 182, 183
warfarin, 134
derivatives, 133
reversal, 38, 39
Werth v. Taylor, 322–3
white blood cells see leukocytes